Pyrantel pamoate

(Redirected from Pyrantel)
Jump to: navigation, search
Pyrantel pamoate
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Pyrantel pamoate is an anthelmintic that is FDA approved for the treatment of pinworms. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, headache and somnolence.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Pyrantel Pamoate Suspension is used for the treatment of pinworms.
  • Dosage:
  • 63-87 lbs. (29-39 kg): 1 1/2 teaspoonful (7.5 mL)
  • 88-112 lbs. (40-50 kg): 2 teaspoonful (10.0 mL)
  • 113-137 lbs. (51-62 kg): 2 1/2 teaspoonful (12.5 mL)
  • 138-162 lbs. (63-73 kg): 3 teaspoonful (15.0 mL)
  • 163-187 lbs. (74-84 kg): 3 1/2 teaspoonful (17.5 mL)
  • 188 lbs. (85 kg and over): 4 teaspoonful (20.0 mL)

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pyrantel pamoate in adult patients.

Non–Guideline-Supported Use

  • Dosage: A single dose of 11 milligrams/kilogram [1]
  • Dosage: 11 milligrams/kilogram in a single dose, repeated twice, 2 weeks apart [2]
  • 11 milligrams/kilogram/day for 3 days [3]
  • Dosage: 11 milligrams/kilogram (maximum 1 gram) [4]

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Pyrantel Pamoate Suspension is used for the treatment of pinworms in children 2 years to 12 years of age.
  • Dosage:
  • Less than 25 lbs. (11 kg) or under 2 years old: Do not use unless directed by a physician
  • 25-37 lbs. (11-16 kg): 1/2 teaspoonful (2.5 mL)
  • 38-62 lbs. (17-28 kg): 1 teaspoonful (5.0 mL)
  • 63-87 lbs. (29-39 kg): 1 1/2 teaspoonful (7.5 mL)
  • 88-112 lbs. (40-50 kg): 2 teaspoonful (10.0 mL)
  • 113-137 lbs. (51-62 kg): 2 1/2 teaspoonful (12.5 mL)
  • 138-162 lbs. (63-73 kg): 3 teaspoonful (15.0 mL)
  • 163-187 lbs. (74-84 kg): 3 1/2 teaspoonful (17.5 mL)
  • 188 lbs. (85 kg and over): 4 teaspoonful (20.0 mL)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pyrantel pamoate in pediatric patients.

Non–Guideline-Supported Use

  • Dosage: A single dose of 11 milligrams/kilogram [1]
  • Dosage: 11 milligrams/kilogram in a single dose, repeated twice, 2 weeks apart [2]
  • 11 milligrams/kilogram/day for 3 days [3]
  • Dosage: 11 milligrams/kilogram (maximum 1 gram) [4]

Contraindications

  • Pregnant
  • Liver disease

Warnings

  • Keep this and all mediactions out of reach of children.
  • In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

There is limited information regarding Pyrantel pamoate Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Pyrantel pamoate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C There is no FDA guidance on usage of Pyrantel pamoate in women who are pregnant.
Pregnancy Category (AUS): B2 There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pyrantel pamoate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pyrantel pamoate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pyrantel pamoate in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Pyrantel pamoate in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Pyrantel pamoate in geriatric settings.

Gender

There is no FDA guidance on the use of Pyrantel pamoate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pyrantel pamoate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pyrantel pamoate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pyrantel pamoate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pyrantel pamoate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pyrantel pamoate in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Monitoring

There is limited information regarding Pyrantel pamoate Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Pyrantel pamoate and IV administrations.

Overdosage

There is limited information regarding Pyrantel pamoate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

Template:Chembox E number
Pyrantel pamoate
IUPAC name 4-[(3-Carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid; 1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
MeSH Pyrantel+pamoate
Properties
C34H30N2O6S
Molar mass 594.6768
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Pyrantel pamoate Mechanism of Action in the drug label.

Structure

There is limited information regarding Pyrantel pamoate Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pyrantel pamoate Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Pyrantel pamoate Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Pyrantel pamoate Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Pyrantel pamoate Clinical Studies in the drug label.

How Supplied

Pyrantel pamoate suspension 32 fl. oz. (946 mL)

Storage

Store at 20°–25° C (68°–77° F)

Images

Drug Images

Package and Label Display Panel

Pyrantel pamoate FDA package label.png
Pyrantel pamoate 32 fl. oz. (946 mL).png
This image of the FDA label is provided by the National Library of Medicine.

Patient Counseling Information

There is limited information regarding Pyrantel pamoate Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Pyrantel pamoate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • Ascarel [5]
  • Pamix
  • Pin-X

Look-Alike Drug Names

There is limited information regarding Pyrantel pamoate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. 1.0 1.1 Ghadirian E, Sanati A, Misaghian G, Yossefi A (1972). "Treatment of ascariasis with pyrantel pamoate in Iran". J Trop Med Hyg. 75 (10): 195–7. PMID 4564698.
  2. 2.0 2.1 "Drugs for parasitic infections". Med Lett Drugs Ther. 35 (911): 111–22. 1993. PMID 8246830.
  3. 3.0 3.1 "Drugs for parasitic infections". Med Lett Drugs Ther. 34 (865): 17–26. 1992. PMID 1567506.
  4. 4.0 4.1 "Drugs for parasitic infections". Med Lett Drugs Ther. 37 (961): 99–108. 1995. PMID 7476669.
  5. "FDA LABEL: PYRANTEL PAMOATE- pyrantel pamoate suspension".



Linked-in.jpg